Book DHT Test in Durg | Dihydrotestosterone Blood Test

The Dihydrotestosterone test is a blood test that measures the level of DHT, a potent androgenic steroid hormone derived from testosterone through the action of the enzyme 5-alpha reductase. DHT is approximately two to three times more biologically potent than testosterone itself, binding to androgen receptors with significantly greater affinity and producing more intense androgenic effects in target tissues. The conversion of testosterone to DHT occurs primarily in androgen-sensitive tissues including the prostate gland, skin, hair follicles, and liver, meaning DHT exerts its most pronounced effects locally within these tissues rather than acting as a circulating systemic hormone in the way testosterone does. DHT plays an indispensable role in male sexual development and differentiation during foetal life, driving the development of the external male genitalia, prostate gland, and male urethra. In adult men, DHT is responsible for the continued growth and function of the prostate, the development of terminal body and facial hair, and paradoxically, the miniaturisation of scalp hair follicles that underlies androgenetic alopecia, the most common form of pattern hair loss in both men and women. In women, DHT is produced in smaller quantities from adrenal and ovarian androgen precursors and plays a role in androgen-dependent conditions including hirsutism and female pattern hair loss. In India, conditions associated with DHT dysregulation including benign prostatic hyperplasia, androgenetic alopecia, and polycystic ovary syndrome are among the most prevalent hormonal disorders, making DHT measurement an increasingly relevant clinical investigation. The test is performed on a small blood sample drawn from a vein and completed in under five minutes.

Doctors prescribe a DHT test in the following situations: Investigating androgenetic alopecia in men and women with progressive scalp hair loss where elevated DHT levels confirm androgen-driven follicular miniaturisation as the underlying mechanism, informing treatment decisions regarding 5-alpha reductase inhibitors such as finasteride and dutasteride that reduce DHT production and slow hair loss progression. Evaluating benign prostatic hyperplasia in men with lower urinary tract symptoms including urinary frequency, urgency, nocturia, weak stream, and incomplete bladder emptying where DHT measurement helps assess the androgenic contribution to prostatic enlargement and guides decisions regarding 5-alpha reductase inhibitor therapy. Assessing ambiguous genitalia and disorders of sexual differentiation in neonates and children where DHT deficiency caused by 5-alpha reductase deficiency syndrome results in undervirilisation of the external genitalia in genetically male individuals despite normal testosterone production, requiring specialist endocrinological and genetic evaluation. Monitoring response to 5-alpha reductase inhibitor therapy in men being treated for benign prostatic hyperplasia or androgenetic alopecia where serial DHT measurements confirm adequate pharmacological suppression of DHT production and guide dose optimisation to achieve the desired therapeutic effect. Investigating hirsutism and female pattern hair loss in women with polycystic ovary syndrome and adrenal androgen excess where elevated DHT alongside testosterone and DHEAS contributes to the androgenic symptom burden and where DHT measurement helps characterise the peripheral androgen activation contributing to clinical manifestations. Evaluating delayed or precocious puberty in adolescents where DHT measurement alongside testosterone, LH, and FSH helps characterise the hormonal profile and identify specific enzymatic defects in androgen metabolism that require targeted treatment.

The DHT test measures the concentration of dihydrotestosterone in the blood, expressed in picograms per millilitre (pg/mL) or nanograms per decilitre (ng/dL). Reference ranges differ significantly between men and women and vary with age and pubertal status. Normal ranges are 300 to 850 pg/mL in adult men and 24 to 368 pg/mL in adult women. Values in prepubertal children are very low and rise progressively through puberty toward adult reference ranges under the influence of increasing gonadal and adrenal androgen production. Normal A result within the gender and age appropriate reference range indicates that DHT production and peripheral androgen activation are within expected physiological limits. In patients being evaluated for androgenetic alopecia or prostatic disease, a normal DHT does not exclude androgen sensitivity at the tissue level, as receptor sensitivity and local 5-alpha reductase activity can vary independently of circulating DHT concentrations. Low DHT A low DHT result may indicate 5-alpha reductase deficiency, hypogonadism, or effective pharmacological suppression of DHT in patients on 5-alpha reductase inhibitor therapy. In male neonates and children, low DHT causing inadequate virilisation requires urgent specialist evaluation to identify the underlying enzymatic defect and plan appropriate hormonal and surgical management. Elevated DHT An elevated DHT result indicates increased peripheral conversion of testosterone to DHT, which may be seen in androgenetic alopecia, benign prostatic hyperplasia, polycystic ovary syndrome, adrenal androgen excess, and anabolic steroid use. In women, elevated DHT contributes to hirsutism, acne, and female pattern hair loss, while in men it is associated with progressive prostatic enlargement and accelerated scalp hair follicle miniaturisation requiring clinical management.

Fasting for 8 to 10 hours before the DHT test is recommended, particularly when ordered alongside testosterone, SHBG, LH, FSH, and other hormonal parameters as part of a comprehensive androgen panel. Water is permitted during the fasting period. Morning collection between 7 AM and 10 AM is strongly preferred as DHT, like testosterone, follows a diurnal pattern with peak levels in the morning, and morning sampling ensures consistency and comparability across serial measurements. Inform your doctor about all medications currently being taken before the test, particularly 5-alpha reductase inhibitors including finasteride and dutasteride, anabolic steroids, testosterone replacement therapy, oral contraceptives, anti-androgen medications such as spironolactone and cyproterone acetate, and any herbal supplements with known androgenic or anti-androgenic properties, as these directly and significantly alter DHT levels and are essential context for accurate result interpretation. If you are undergoing serial DHT measurements to monitor treatment response to 5-alpha reductase inhibitor therapy, maintaining strict consistency in the timing of the last medication dose relative to sample collection, the time of day of collection, and use of the same laboratory assay platform ensures reliable and clinically meaningful trend comparison across visits. Staying well hydrated before the blood draw facilitates easier venous access and a smooth collection experience.

If you are booking through the SecondMedic platform the DHT test price in Durg can cost you around Rs. 1150. You may also consider booking a comprehensive androgen panel that includes DHT alongside total testosterone, free testosterone, SHBG, DHEAS, LH, and FSH for a complete assessment of androgenic hormonal status at a bundled price on SecondMedic.

SecondMedic offers convenient home sample collection for the DHT test in Durg, making it easy to get tested without visiting a diagnostic centre. Home collection is available free of charge for orders above Rs. 300. A trained phlebotomist will visit your preferred address between 7 AM and 10 PM, seven days a week, including Sundays and public holidays. Your blood sample is processed at NABL-accredited partner laboratories, and your report is delivered within 24 hours directly to your WhatsApp and email.